G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1.

IF 8.1 1区 生物学 Q1 CELL BIOLOGY Cell Death & Disease Pub Date : 2024-11-02 DOI:10.1038/s41419-024-07156-w
Francisco Exposito, Miriam Redrado, Diego Serrano, Silvia Calabuig-Fariñas, Aida Bao-Caamano, Sandra Gallach, Eloisa Jantus-Lewintre, Angel Diaz-Lagares, Aitor Rodriguez-Casanova, Juan Sandoval, Edurne San Jose-Eneriz, Javier Garcia, Esther Redin, Yaiza Senent, Sergio Leon, Ruben Pio, Rafael Lopez, Julen Oyarzabal, Antonio Pineda-Lucena, Xabier Agirre, Luis M Montuenga, Felipe Prosper, Alfonso Calvo
{"title":"G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1.","authors":"Francisco Exposito, Miriam Redrado, Diego Serrano, Silvia Calabuig-Fariñas, Aida Bao-Caamano, Sandra Gallach, Eloisa Jantus-Lewintre, Angel Diaz-Lagares, Aitor Rodriguez-Casanova, Juan Sandoval, Edurne San Jose-Eneriz, Javier Garcia, Esther Redin, Yaiza Senent, Sergio Leon, Ruben Pio, Rafael Lopez, Julen Oyarzabal, Antonio Pineda-Lucena, Xabier Agirre, Luis M Montuenga, Felipe Prosper, Alfonso Calvo","doi":"10.1038/s41419-024-07156-w","DOIUrl":null,"url":null,"abstract":"<p><p>The treatment of non-small cell lung cancer (NSCLC) patients has significantly improved with recent therapeutic strategies; however, many patients still do not benefit from them. As a result, new treatment approaches are urgently needed. In this study, we evaluated the antitumor efficacy of co-targeting G9a and DNMT1 enzymes and its potential as a cancer drug sensitizer. We observed co-expression and overexpression of G9a and DNMT1 in NSCLC, which were associated with poor prognosis. Co-targeting G9a/DNMT1 with the drug CM-272 reduced proliferation and induced cell death in a panel of human and murine NSCLC cell lines. Additionally, the transcriptomes of these cells were reprogrammed to become highly responsive to chemotherapy (cisplatin), targeted therapy (trametinib), and epigenetic therapy (vorinostat). In vivo, CM-272 reduced tumor volume in human and murine cell-derived cancer models, and this effect was synergistically enhanced by cisplatin. The expression of SCARA5 and AOX1 was induced by CM-272, and both proteins were found to be essential for the antiproliferative response, as gene silencing decreased cytotoxicity. Furthermore, the expression of SCARA5 and AOX1 was positively correlated with each other and inversely correlated with G9a and DNMT1 expression in NSCLC patients. SCARA5 and AOX1 DNA promoters were hypermethylated in NSCLC, and SCARA5 methylation was identified as an epigenetic biomarker in tumors and liquid biopsies from NSCLC patients. Thus, we demonstrate that co-targeting G9a/DNMT1 is a promising strategy to enhance the efficacy of cancer drugs, and SCARA5 methylation could serve as a non-invasive biomarker to monitor tumor progression.</p>","PeriodicalId":9734,"journal":{"name":"Cell Death & Disease","volume":null,"pages":null},"PeriodicalIF":8.1000,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531574/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Death & Disease","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1038/s41419-024-07156-w","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The treatment of non-small cell lung cancer (NSCLC) patients has significantly improved with recent therapeutic strategies; however, many patients still do not benefit from them. As a result, new treatment approaches are urgently needed. In this study, we evaluated the antitumor efficacy of co-targeting G9a and DNMT1 enzymes and its potential as a cancer drug sensitizer. We observed co-expression and overexpression of G9a and DNMT1 in NSCLC, which were associated with poor prognosis. Co-targeting G9a/DNMT1 with the drug CM-272 reduced proliferation and induced cell death in a panel of human and murine NSCLC cell lines. Additionally, the transcriptomes of these cells were reprogrammed to become highly responsive to chemotherapy (cisplatin), targeted therapy (trametinib), and epigenetic therapy (vorinostat). In vivo, CM-272 reduced tumor volume in human and murine cell-derived cancer models, and this effect was synergistically enhanced by cisplatin. The expression of SCARA5 and AOX1 was induced by CM-272, and both proteins were found to be essential for the antiproliferative response, as gene silencing decreased cytotoxicity. Furthermore, the expression of SCARA5 and AOX1 was positively correlated with each other and inversely correlated with G9a and DNMT1 expression in NSCLC patients. SCARA5 and AOX1 DNA promoters were hypermethylated in NSCLC, and SCARA5 methylation was identified as an epigenetic biomarker in tumors and liquid biopsies from NSCLC patients. Thus, we demonstrate that co-targeting G9a/DNMT1 is a promising strategy to enhance the efficacy of cancer drugs, and SCARA5 methylation could serve as a non-invasive biomarker to monitor tumor progression.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
G9a/DNMT1 协同靶向抑制非小细胞肺癌的生长,并通过 SCARA5 和 AOX1 重编程肿瘤细胞,使其对抗癌药物做出反应。
近年来,非小细胞肺癌(NSCLC)患者的治疗策略有了明显改善,但仍有许多患者无法从中获益。因此,迫切需要新的治疗方法。在这项研究中,我们评估了联合靶向 G9a 和 DNMT1 酶的抗肿瘤疗效及其作为抗癌药物增敏剂的潜力。我们观察到,G9a和DNMT1在NSCLC中的共表达和过表达与不良预后有关。在一组人类和鼠类 NSCLC 细胞系中,与 CM-272 共同靶向 G9a/DNMT1 的药物可减少细胞增殖并诱导细胞死亡。此外,这些细胞的转录组经过重新编程,对化疗(顺铂)、靶向治疗(曲美替尼)和表观遗传学治疗(伏立诺他)具有高度响应性。在体内,CM-272能减少人和小鼠细胞衍生癌症模型中的肿瘤体积,顺铂能协同增强这种效果。CM-272诱导了SCARA5和AOX1的表达,发现这两种蛋白对于抗增殖反应至关重要,因为基因沉默会降低细胞毒性。此外,在 NSCLC 患者中,SCARA5 和 AOX1 的表达相互正相关,与 G9a 和 DNMT1 的表达成反比。SCARA5和AOX1的DNA启动子在NSCLC中存在高甲基化,SCARA5甲基化在NSCLC患者的肿瘤和液体活检中被鉴定为表观遗传生物标记物。因此,我们证明了联合靶向 G9a/DNMT1 是提高抗癌药物疗效的一种有前途的策略,而 SCARA5 甲基化可作为监测肿瘤进展的一种非侵入性生物标记物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cell Death & Disease
Cell Death & Disease CELL BIOLOGY-
CiteScore
15.10
自引率
2.20%
发文量
935
审稿时长
2 months
期刊介绍: Brought to readers by the editorial team of Cell Death & Differentiation, Cell Death & Disease is an online peer-reviewed journal specializing in translational cell death research. It covers a wide range of topics in experimental and internal medicine, including cancer, immunity, neuroscience, and now cancer metabolism. Cell Death & Disease seeks to encompass the breadth of translational implications of cell death, and topics of particular concentration will include, but are not limited to, the following: Experimental medicine Cancer Immunity Internal medicine Neuroscience Cancer metabolism
期刊最新文献
Author Correction: EGFR-ERK induced activation of GRHL1 promotes cell cycle progression by up-regulating cell cycle related genes in lung cancer. VCP enhances autophagy-related osteosarcoma progression by recruiting USP2 to inhibit ubiquitination and degradation of FASN. G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1. Inhibition of mitochondrial OMA1 ameliorates osteosarcoma tumorigenesis. Ror2 signaling regulated by differential Wnt proteins determines pathological fate of muscle mesenchymal progenitors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1